Overview

Photodynamic Therapy in Treating Patients With Lung Cancer

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with lung cancer. Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed.
Phase:
Phase 1
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborator:
National Cancer Institute (NCI)